Page 55 - 《南京医科大学学报(自然科学版)》2025年第9期
P. 55

第45卷第9期                           南京医科大学学报(自然科学版)
                  2025年9月                   Journal of Nanjing Medical University(Natural Sciences)     ·1267 ·


               ·专题研究:肿瘤·

                监测免疫治疗反应的颗粒酶B靶向分子影像探针研究进展



                杨继辰 ,邱 玲 ,林建国             1,2*
                                1,2
                       1,2
                南京医科大学药学院核药学系,江苏              南京    211166;国家卫生健康委员会核医学重点实验室,江苏省分子核医学重点实验
                1                                         2
                室,江苏省原子医学研究所,江苏 无锡              214063



               [摘   要] 近年来,癌症免疫治疗尤其是免疫检查点抑制剂(immune checkpoint inhibitor,ICI),在临床实践中取得了显著进
                展。然而,由于个体间免疫反应的异质性,患者对治疗的应答具有差异,因此对治疗效果的监测显得尤为重要。在肿瘤微环境
                中,细胞毒性T淋巴细胞(cytotoxic T lymphocyte,CTL)的活性是评估免疫治疗效果的关键指标。颗粒酶B(granzyme B,GzmB)
                作为一种主要存在于CTL中的丝氨酸蛋白酶,是早期预测免疫治疗反应的重要生物标志物。靶向GzmB的分子影像探针可以
                监测免疫治疗过程中肿瘤部位GzmB表达的变化,进而为评估治疗效果提供依据。文章总结了各类GzmB靶向分子探针的研
                究进展,并分析了探针的结构设计、成像原理及其在早期监测肿瘤免疫治疗反应中的应用潜力,旨在为GzmB靶向分子探针的
                进一步开发和临床应用提供参考。
               [关键词] 癌症;免疫治疗;疗效监测;颗粒酶B;分子影像探针
               [中图分类号] R730.51                    [文献标志码] A                    [文章编号] 1007⁃4368(2025)09⁃1267⁃09
                doi:10.7655/NYDXBNSN250417



                Research progress of granzyme B targeted molecular imaging probes for monitoring
                immunotherapy response
                           1,2
                                      1,2
                YANG Jichen ,QIU Ling ,LIN Jianguo 1,2*
                1 Department of Radiopharmaceuticals,School of Pharmacy,Nanjing Medical University,Nanjing 211166;National
                                                                                                        2
                Health Commission Key Laboratory of Nuclear Medicine,Jiangsu Key Laboratory of Molecular Nuclear Medicine,
                Jiangsu Institute of Nuclear Medicine,Wuxi 214063,China


               [Abstract] In recent years,cancer immunotherapy,especially immune checkpoint inhibitor(ICI),has made remarkable progress in
                clinical practice. However,due to the heterogeneity of immune responses among individuals,patients’responses to treatment vary,
                making the monitoring of treatment efficacy particularly important. In the tumor microenvironment,the activity of cytotoxic T
                lymphocyte(CTL)is a key indicator for evaluating the efficacy of immunotherapy. Granzyme B(GzmB),a serine protease mainly
                present in CTLs,is considered as an important biomarker for early prediction of the response to immunotherapy. Molecular imaging
                probes targeting GzmB can monitor the changes in GzmB expression at tumor sites during immunotherapy,providing a basis for
                evaluating treatment efficacy. This review summarizes the research progress of various GzmB⁃targeted molecular probes,and analyzes
                the structural design,imaging principle of the probes and their application potential in early monitoring of tumor immunotherapy
                response,aiming to provide reference for the further development and clinical application of GzmB⁃targeted molecular probes.
               [Key words] cancer;immunotherapy;efficacy monitoring;granzyme B;molecular imaging probe
                                                                            [J Nanjing Med Univ,2025,45(09):1267⁃1275]





                                                                      免疫治疗是一种通过激活或增强患者自身免
                                                                  疫系统诱导抗肿瘤免疫、杀伤癌细胞的疗法,近年
               [基金项目] 国家自然科学基金(22076069)
                                                                                                       [1]
                                                                  来已发展成为临床治疗癌症的重要策略 。免疫
                ∗
                通信作者(Corresponding author),E⁃mail:linjianguo@jsinm.org
               (ORCID:0000⁃0003⁃1018⁃9794)                        检查点抑制剂(immune checkpoint inhibitor,ICI),如
   50   51   52   53   54   55   56   57   58   59   60